Vasonatrin Peptide VNP

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Vasonatrin peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) with potent venodilating and natriuretic activity.

Vasonatrin peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) with potent venodilating and natriuretic activity.(In Vitro):Vasonatrin peptide binds with both natriuretic peptide receptor A and B, but with a preference for B. VNP-stimulated cGMP is 11-fold greater in NPRB than NPRA.(In Vivo):The high-fat diet-fed streptozotocin-induced diabetic Sprague-Dawley rats are subjected to ischemia-reperfusion operation. VNP treatment (100 g/kg iv, 10 min before reperfusion) significantly improved the instantaneous first derivation of left ventricle pressure (LV dP/dtmax) and LV systolic pressure and reduced LV end-diastolic pressure, apoptosis index, caspase-3 activity, plasma creatine kinase (CK), and lactate dehydrogenase (LDH) activities. Treatment hypoxia-induced pulmonary hypertension (HPH) with Vasonatrin peptide for 1 week significantly reduceS mean pulmonary arterial pressure, pulmonary vascular resistance, RVH and muscularization of the pulmonary arteries. Acute intravenous administration of 50 microg/kg Vasonatrin peptide significantly ameliorates pulmonary haemodynamics in HPH rats.

Vasonatrin Peptide (VNP) markedly enhances adiponectin mRNA expression, as well as protein secretion, however, suppresses IL-6 production in mature adipocytes. In addition, VNP significantly increases the intracellular levels of cGMP. The effects of VNP are mimicked by 8-br-cGMP, whereas inhibits by HS-142-1, or KT-5823.

Vasonatrin peptide (100 μg/kg; i.v. ; 10 min before reperfusion) attenuates myocardial ischemia-reperfusion injury in diabetic rats. Animal Model:High-fat diet-fed streptozotocin-induced diabetic Sprague-Dawley ratsDosage:100 μg/kg Administration:I.v. ; 10 min before reperfusionResult:Significantly improved the instantaneous first derivation of left ventricle pressure (±LV dP/dtmax) and LV systolic pressure and reduced LV end-diastolic pressure, apoptosis index, caspase-3 activity, plasma creatine kinase (CK), and lactate dehydrogenase (LDH) activities. Inhibited endoplasmic reticulum (ER) stress by suppressing glucose-regulated protein 78 (GRP78) and C/EBP homologous protein (CHOP).

——

Others

Other Targets

triuretic peptide receptors

——

——

141676-35-9

2865.37

C123H198N36O36S3

>98% (HPLC)

——

——

Sequence:Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bridge: Cys6-Cys22)

(-20℃)

With Ice Pack

≥ 2 years